TY - JOUR
T1 - β-funaltrexamine (β-FNA) and neural tumor response in mice
AU - Zagon, I. S.
AU - McLaughlin, P. J.
AU - Takemori, A. E.
AU - Portoghese, P. S.
N1 - Funding Information:
This research was supported in part by NIH Grants NS-20623, NS-20500 and NS-01533.
PY - 1985/10/8
Y1 - 1985/10/8
N2 - The effects of β-FNA, a highly selective and irreversible μ opioid receptor antagonist, in altering tumor response in A/Jax mice inoculated with S20Y cells were determined. Inoculation of neuroblastoma cells in control subjects resulted in 100% tumor incidence within 16 days, and mean median survival times of 36 and 35 days, respectively, following tumor inoculation. Tumor incidence and survival times were comparable to controls for mice given chronic injections of 2 mg/kg and 10 mg/kg β-FNA every 48 h beginning 2 days after tumor inoculation. Tumor growth was subnormal in the 10 mg/kg β-FNA group. Both dosages of β-FNA were found to block morphine-induced analgesia for 48 h. These results suggests that, in and by themselves, μ receptors selectively antagonized by β-FNA do not play an important role in neuro-oncogenic events.
AB - The effects of β-FNA, a highly selective and irreversible μ opioid receptor antagonist, in altering tumor response in A/Jax mice inoculated with S20Y cells were determined. Inoculation of neuroblastoma cells in control subjects resulted in 100% tumor incidence within 16 days, and mean median survival times of 36 and 35 days, respectively, following tumor inoculation. Tumor incidence and survival times were comparable to controls for mice given chronic injections of 2 mg/kg and 10 mg/kg β-FNA every 48 h beginning 2 days after tumor inoculation. Tumor growth was subnormal in the 10 mg/kg β-FNA group. Both dosages of β-FNA were found to block morphine-induced analgesia for 48 h. These results suggests that, in and by themselves, μ receptors selectively antagonized by β-FNA do not play an important role in neuro-oncogenic events.
UR - http://www.scopus.com/inward/record.url?scp=0022413025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022413025&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(85)90198-0
DO - 10.1016/0014-2999(85)90198-0
M3 - Article
C2 - 4054212
AN - SCOPUS:0022413025
SN - 0014-2999
VL - 116
SP - 165
EP - 169
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-2
ER -